Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung(Bone Health and Osteoporosis Foundation), Andreas Grauer(Omeros Corporation (United States)), Henry G. Bone(University of Arizona), José Zanchetta(Universidad del Salvador), Jacques P. Brown(Centre hospitalier de l'Université Laval), Michael A. Bolognese, Judy Maddox(Amgen (United States)), Heinrich Resch, Adolfo Díez‐Pérez(Tufts University), John Caminis(UCB Pharma (Belgium)), Stefan Goemaere(Ghent University Hospital), Paul Meisner(UCB Pharma (Belgium)), Sarah Bray(MRC Biostatistics Unit)
Cited by 237
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712